Is TG THERAPEUTICS, INC. (TGTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.4% / 30% | 3.0% / 30% | 6.5% / 30% | 1.75% / 5% | ✓ HALAL |
| DJIM | 5.4% / 33% | 3.0% / 33% | 6.5% / 33% | 1.75% / 5% | ✓ HALAL |
| MSCI | 23.9% / 33% | 13.4% / 33% | 28.7% / 33% | 1.75% / 5% | ✓ HALAL |
| S&P | 5.4% / 33% | 3.0% / 33% | 6.5% / 33% | 1.75% / 5% | ✓ HALAL |
| FTSE | 23.9% / 33% | 13.4% / 33% | 28.7% / 50% | 1.75% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 83.7% | |
| Operating Margin | 26.2% | |
| Net Margin | 72.6% | |
| Return on Equity (ROE) | 102.8% | |
| Return on Assets (ROA) | 9.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$25M |
| Free Cash Flow | -$25M |
| Total Debt | $254M |
| Debt-to-Equity | 39.3 |
| Current Ratio | 4.1 |
| Total Assets | $1.1B |
Price & Trading
| Last Close | $31.98 |
| 50-Day MA | $29.80 |
| 200-Day MA | $32.13 |
| Avg Volume | 2.1M |
| Beta | 1.9 |
|
52-Week Range
$25.28
| |
About TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Purification Calculator
As a halal stock with 1.75% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is TG THERAPEUTICS, INC. (TGTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), TG THERAPEUTICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is TG THERAPEUTICS, INC.'s debt ratio?
TG THERAPEUTICS, INC.'s debt ratio is 5.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 23.9%.
Does TG THERAPEUTICS, INC. require dividend purification?
Yes, TG THERAPEUTICS, INC. has an impermissible income ratio of 1.75%, which means 1.75% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are TG THERAPEUTICS, INC.'s key financial metrics?
TG THERAPEUTICS, INC. has a market capitalization of $5.1B, trailing P/E ratio of 11.5, and revenue of $616M. The company maintains a gross margin of 83.7% and a net margin of 72.6%. Return on equity stands at 102.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.